The height of the COVID-19 pandemic is in the rear view, but the vaccine pipeline promises plenty of other activity in the coming year in established markets like respiratory syncytial virus as well as emerging diseases like dengue, mpox and chikungunya, a Pink Sheet infographic analysis shows.
A battle royale is brewing in RSV, where GSK plc and Pfizer Inc. are vying to launch the first vaccine for the common infection, which can lead to severe disease in high-risk populations like infants and the elderly
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?